JR Pharma Engineering ApS: Financial statements 2024
CVR: 42398993
Source: annual report 2024, Danish Business Authority
01/07/2023 – 30/06/2024
JR Pharma Engineering ApS (CVR 42398993) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 1,959,825 and a net result of DKK 650,721 compared with DKK 645,284 the year before. That is an increase of 5.1% compared with the year before. The profit margin was 33.2%. Equity in the 2024 report amounted to DKK 692,663. The solvency ratio was 63.6%.
- Revenue
- DKK 1,959,825
- Gross Profit
- DKK 1,947,122
- Profit/Loss
- DKK 650,721
- Equity
- DKK 692,663
- Total Assets
- DKK 1,089,413
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 2 mio. | 1.9 mio. | 651 t. | 693 t. | - |
| 2023 | 1.9 mio. | 1.8 mio. | 645 t. | 687 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout JR Pharma Engineering ApS
JR Pharma Engineering ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2021. The company is registered under the industry Rådgivende ingeniøraktiviteter inden for byggeri og anlægsarbejder. The management consists of Jimmy Rønne Jensen. The company is owned by JR Pharma Engineering Holding ApS. In 2026, the company reported revenue of DKK 2,000,220 and a net result of DKK 432,091 compared with DKK 591,630 the year before. Equity in the 2026 report amounted to DKK 474,033.